Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, one-arm, exploratory clinical study to observe and evaluate the
efficacy and safety of Anlotinib hydrochloride capsules in patients with advanced liver
cancer.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University